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Abstract
To follow‐up on our previous report that acarbose (ACA), a drug that blocks
postprandial glucose spikes, increases mouse lifespan, we studied ACA at three
doses: 400, 1,000 (the original dose), and 2,500 ppm, using genetically heteroge-
neous mice at three sites. Each dose led to a significant change (by log‐rank test) in
both sexes, with larger effects in males, consistent with the original report. There
were no significant differences among the three doses. The two higher doses
produced 16% or 17% increases in median longevity of males, but only 4% or 5%
increases in females. Age at the 90th percentile was increased significantly (8%–
11%) in males at each dose, but was significantly increased (3%) in females only at
1,000 ppm. The sex effect on longevity is not explained simply by weight or fat
mass, which were reduced by ACA more in females than in males. ACA at
*These three authors contributed equally to this study.
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1,000 ppm reduced lung tumors in males, diminished liver degeneration in both
sexes and glomerulosclerosis in females, reduced blood glucose responses to refeed-
ing in males, and improved rotarod performance in aging females, but not males.
Three other interventions were also tested: ursolic acid, 2‐(2‐hydroxyphenyl) ben-
zothiazole (HBX), and INT‐767; none of these affected lifespan at the doses tested.
The acarbose results confirm and extend our original report, prompt further atten-
tion to the effects of transient periods of high blood glucose on aging and the dis-
eases of aging, including cancer, and should motivate studies of acarbose and other
glucose‐control drugs in humans.
K E YWORD S
acarbose, health measures, heterogeneous mice, lifespan
1 | INTRODUCTION
The ITP finds interventions that improve mammalian lifespan, and
the current study determines optimal doses of ACA. These studies
suggest new insights into the factors that modulate aging rates and
may lead to treatments useful in the clinic. Such interventions also
suggest hypotheses for basic research, as different biological systems
are compared, and different models of delayed aging contrasted to
distinguish changes essential in delaying aging.
The ITP design, presented at this URL: (http://www.nia.nih.gov/
research/dab/interventions-testing-program-itp), uses genetically
heterogeneous (UM‐HET3) mice, the offspring of the CByB6F1 ×
C3D2F1 cross. Such crosses of two diverse F1 hybrids, representing
four different inbred strains, produce genetically heterogeneous pop-
ulations in which each animal is unique, but a full sibling of all other
mice in the population, so that the cross is reproducible (Roderick,
1963). Use of genetically diverse individuals minimizes the possibility
that characteristics of a single inbred or F1 hybrid genotype might
be confused with those of the species. The ITP includes replication
at three sites, with sufficient mice to give more than 80% power to
detect a change of 10% in mean lifespan, even if only two of the
three sites contribute data. This design was detailed previously (Har-
rison et al., 2009, 2014; Miller et al, 2011, 2014; Strong et al., 2008,
2013, 2016).
The interventions for this study were chosen for the following
reasons:
1. Acarbose (ACA) is a candidate to replicate some aspects of diet
or caloric restriction. Archer (2003) suggests that the postmeal
spike in glucose may contribute to aging. This spike is reduced
by ACA (Balfour & McTavish, 1993). Acarbose has been widely
used clinically to prevent postprandial hyperglycemia, and several
reports (Frantz et al., 2005; Miyamura et al., 2010) demonstrate
its ability to reduce or prevent postprandial hyperglycemia in
mice. The glucose spike during a meal is blunted because acar-
bose inhibits α‐glucosidase, thus reducing the rate at which
polysaccharides are digested, as well as reducing sugar uptake. It
does not sequester glucose, nor block its uptake—it blocks its
release from complex polysaccharides.
Like chronic diet restriction (DR), chronic ACA treatment
reduces body weight and body fat, and also improves glucose dys-
regulation associated with aging (Yamamoto & Otsuki 2006). How-
ever, unlike DR, food intake is often increased, not reduced, during
long‐term ACA treatment (Yamamoto & Otsuki 2006). Importantly,
ACA increases HET3 mouse lifespans more effectively in males
than in females (Harrison et al., 2014; Strong et al., 2016), while
DR increases lifespan to a similar degree in both (Flurkey et al.,
2010).
Once a longevity study has shown a benefit at the drug dose
tested initially, it is very useful to evaluate the same drug over a
wider range of doses to try to determine the optimal dose for bene-
ficial effect. Lower doses could, in principle, be more effective than
the original dose, if the lower dose mitigates harmful side effects.
Doses above the one originally tested could, in principle, be more
effective, if benefits are proportional to drug concentrations over
the tested range. A drug that led to sex‐specific benefits at the origi-
nal dose may, in principle, show strong effects in both sexes, if, for
example, its blood or tissue concentration is affected by sex‐specific
metabolic pathways. Better definition of optimal drug dose is also
very helpful in providing a foundation for further studies. For these
reasons, three different doses of ACA are tested here.
2. Ursolic acid (UA) decreased d‐galactose (D‐gal)‐induced neurotox-
icity in mice (Lu et al., 2007) and also inhibited cognitive impair-
ment induced by a high‐fat diet (Lu et al., 2011). Kunkel et al.
(2012) found that UA increased skeletal muscle mass and func-
tion while improving glucose tolerance and reducing obesity.
These results suggest that UA might benefit deleterious effects
of age.
3. 2‐(2‐hydroxyphenyl) benzothiazole (HBX) is a compound with
similar structural features to the flavonoid Thioflavin T (4‐(3,6‐
dimethyl‐1,3‐benzothiazol‐3‐ium‐2‐yl)‐N,N‐dimethylaniline
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chloride), a molecule used in histopathology to stain amyloid in
tissues. These molecules are able to maintain protein homeostasis
during aging, and to increase median and maximal lifespans in
C. elegans (Alavez et al., 2011).
4. INT‐767d (6α‐ethyl‐24‐nor‐5β‐cholane‐3α,7α,23‐triol‐23 sulfate
sodium salt) is a dual FXR/TGR5 activating agonist. Activating the
bile acid‐activated nuclear hormone receptor FXR, and the G protein
coupled receptor TGR5, reduces several diseases of aging, including
chronic liver and kidney disease as well as diabetes (Rizzo et al.,
2010). Chronic treatment of aging mice with INT‐767d could, in
principle, retard these diseases as well as other deleterious aspects
of aging (Fiorucci, Mencarelli, Palladino, & Cipriani, 2009; Hylemon
et al., 2009; Wang et al, 2017). Dwarf mouse models with increased
lifespan also have increased serum and liver bile acid levels and FXR
activation, which supports this idea (Gems, 2007).
2 | RESULTS
2.1 | Lifespan and body weight
Mice were fed ACA at three different doses: low—400, medium—
1,000, and high—2,500 mg per kg diet (ppm) from 8 months of age.
Using data pooled across the three sites, ACA had significant effects
by the log‐rank test on female median lifespans at all three doses. At
medium and high doses, median lifespan increased 5% (p = 0.003)
and 4% (p = 0.006), respectively. The lowest dose of ACA did not
change median survival (0% increase), but significantly (p = 0.03)
improved survival at ages greater than the median (Table 1, Fig-
ure 1a). ACA had much more benefit in males, whose median lifes-
pans were increased by the three doses by 11%, 17%, and 16%,
respectively, all highly (p < 0.0001) significant (Table 1, Figure 1b).
None of the effects on lifespan of the three ACA doses were signifi-
cantly different from the other two doses in either males or females.
We used the 90th percentile as a surrogate for maximum lifespan,
and the Wang/Allison test (Wang, Li, Redden, Weindruch, & Allison,
2004) in pooled data also showed much larger benefits in males. The
low, medium, and high doses of ACA caused increases of 2%, 3%,
and 3% (p = 0.37, 0.007, 0.10), respectively, in females, and 11%,
11%, and 8% (p = 0.0004, 0.0004, 0.0001), respectively, in males
(Table 1). Neither UA, I767 nor HBX changed lifespan significantly in
either males or females at the doses used.
Site differences showed the importance of replication (Table 2) and
the value of pooling data to increase sample size and statistical power.
Effects of ACA were not significant in females at either TJL or UM,
although they were at UT ranging from p = 0.02 to 0.03. In males, all
TABLE 1 Effects of three different doses of ACA on lifespan
Group N
Median lifespan Lifespan at 90th percentile
Days % change p‐value Days % change Wang–Allison p‐value
Females
Cont_13 287 889 1,097
ACA_lo 139 887 0% 0.03 1,123 2% 0.37
ACA_mid 142 933 5% 0.003 1,125 3% 0.007
ACA_hi 152 922 4% 0.006 1,125 3% 0.10
UA 147 885 0% 0.49 1,084 –1% 0.46
Cont_12 279 877 1,100
HBX 136 856 –2% 0.4 1,091 –1% NS
I767d 136 868 –1% 0.8 1,102 0% NS
Males
Cont_13 273 830 1,089
ACA_lo 147 918 11% <0.0001 1,211 11% 0.0004
ACA_mid 161 975 17% <0.0001 1,210 11% 0.0004
ACA_hi 163 964 16% <0.0001 1,181 8% 0.0001
UA 151 883 6% 0.38 1,092 0% 0.91
Cont_12 284 816 1,055
HBX 155 822 1% 0.4 1,069 1% NS
I767d 147 791 –3% 0.11 1,012 –4% NS
Note. Lifespans of ITP mice from cohorts 2013 and 2012. Cont_13 = controls for cohort started in 2013; Cont_12 = controls for cohort started in
2012. N = number of mice tested; data were pooled, with about 1/3 from each testing site. Probabilities that lifespans are the same as the controls in
column 4 (p‐value) used two‐tailed log‐rank test on pooled data stratified by sites; “removed” mice were included in these calculations. Probabilities that
the proportion of live mice is the same in treated as in the control group at the 90th percentile age are evaluated by the procedure of Wang et al.,
(2004). Amounts of ACA in diet: hi = 2,500 ppm; mid = 1,000 ppm; lo = 400 ppm. UA, HBX, and 1767d had no significant effect on lifespan in the
doses used.
NS: not significant.
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three doses of ACA increased lifespan significantly at TJL and UT
(p = 0.002 to <0.0001); only the 1,000 ppm dose gave a significant
increase in male lifespan at UM (p = 0.006). Percentage increases in
lifespan—given for diets containing 400, 1,000, and 2,500 ppm ACA,
respectively, in Table 2—also were larger at TJL (10, 20, 20) and UT (14,
13, 19) than at UM (1, 13, 7), perhaps reflecting the 14% longer lifespan
of control males at the UM site. As in past ITP cohorts, lifespan for con-
trol females was similar at all three sites (median values at TJL—
890 days, UM—870 days, and UT—897 days), but longer for males at
UM (TJL—803 days, UM—912 days, and UT—807 days).
F IGURE 1 Effects of ACA on lifespan and body weight. Effects of dietary ACA dose on: (a, b) lifespans; (c, d) body weights over lives of
the same mice. Lifespan curves (a and b for females and males) show the entire lifespan from the data used to produce Table 1, which
includes sample sizes and statistical analyses of differences in median and 90th percentile values from the control as a result of each ACA
dose. Body weights (c and d for females and males) represent 115–165 mice tested at 6, 12, 18, and 24 months of age in the ACA‐fed groups.
Numbers of controls were about twice as high. Using one‐way ANOVA with Sidak post hoc test, there was no effect of ACA at 6 months. At
12 and 18 months, weights were significantly different as shown by >: Males – Control, ACA_lo > ACA_hi, ACA_mid; Females –
Control > ACA_lo > ACA_mid, ACA_hi. At 24 months of age, there were no significant differences between Control and treated males, while
in Females – Control, ACA_Lo > ACA_hi, ACA_mid. Weights at 24 months are hard to interpret, due to unbalanced death rates at the three
sites, and possible weight loss due to ill health
TABLE 2 Effects of ACA on median lifespan at each ITP site
Group
TJL UM UT
Mean % changeDays % change p‐value Days % change p‐value Days % change p‐value
Females
Cont_13 890 870 897
ACA_lo 887 0% 0.43 871 0% 0.49 923 3% 0.03 1%
ACA_mid 934 4% 0.33 890 1% 0.06 950 4% 0.02 3%
ACA_hi 938 6% 0.13 931 6% 0.32 917 2% 0.03 5%
Males
Cont_13 803 912 807
ACA_lo 880 10% 0.001 924 1% 0.21 919 14% 0.0006 8%
ACA_mid 967 20% 0.000 1,033 13% 0.006 914 13% 0.002 16%
ACA_hi 960 20% 0.000 975 7% 0.21 957 19% 0.000 15%
Note. For each site, this table lists median lifespans, % change, and the log‐rank p‐value from the control (Cont_13) for mice fed the three different
doses of ACA starting at 8 months of age. A p‐value of 0.000 means p < 0.001. The rightmost column shows averages (“Mean % change”) of median
changes across the three sites.
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Using pooled data from the same mice, when fed 1,000 or
2,500 ppm ACA, body weights averaged 4–6 g lower in females at
12, 18, and 24 months of age (Figure 1c) and 2–4 g lower in males
at 12 and 18 months of age (Figure 1d). Statistically, female controls
were the heaviest at 12 and 18 months, with females fed 400 ppm
ACA next most heavy. Those fed 1,000 or 2,500 ppm ACA were the
lightest, with similar body weights (Figure 1c). At 12 and 18 months,
male controls and those fed 400 ppm ACA were the most heavy,
while those fed 1,000 or 2,500 ppm ACA were lighter, and not sig-
nificantly different from each other (Figure 1d).
2.2 | Body composition
Acarbose at 1,000 ppm was fed to separate groups of mice starting
at 4 months of age, and weights and body composition then evalu-
ated at two sites. At TJL and UT, fat and lean weights were mea-
sured by NMR body composition analysis, using the echo MRITM 3‐
in‐1 (Table 2), in which grams of fat are the mass of the body's fat
molecules expressed as g of canola oil, while grams of lean are mus-
cle tissue mass equivalent of all body parts containing water, exclud-
ing fat, bone, and substances that do not contribute to the NMR
signal, such as hair, teeth, and claws. Testing the same groups of
ACA‐fed and age‐ and sex‐matched control mice at 16–17, 22–23
and 29–30 months of age, ACA reduced body and fat weights signif-
icantly in females, but had no significant effects on these measures
in males. Lean mass was not affected by ACA in either sex (Table 2).
At UT, ACA diets also had greater effects in females, reducing body
weights by 8–12 g in females at 12–22 months of age (Figure 2a),
and by 6–8 g in males over the same age range (Figure 2d). The
decrease in % female body fat (Figure 2b) was about twice as great
as in males (Figure 2e), while the increase in % lean mass in females
fed ACA (Figure 3c) was two to three times greater than in males
(Figure 2f).
A separate set of data from UM defined the effects of ACA
feeding on four fat depots using HET3 mice at 12 months of age
(Figure 3). In subscapular fat, there were no ACA effects in females,
but highly significant effects in males (p < 0.001). In mesenteric fat,
ACA caused highly significant reductions in both sexes (both
p < 0.001). In gonadal fat, ACA effects were also similar in both
sexes, but did not reach statistical significance, and in inguinal fat,
ACA had no effect (Figure 3).
2.3 | Pathology
As illustrated in Figure 4, males fed ACA had about half as many lung
tumors as controls, but ACA feeding did not reduce the already low
frequency of lung tumors in females. The frequency of adrenal
medullary vasodilation was reduced to an equivalent extent in both
sexes, reaching statistical significance in females, and in the pooled
data, though not in males (Figure 4). Replicating results reported by
Strong et al. (2016), ACA reduced the incidence of liver degeneration
in both male and female UM‐HET3 mice, but only results in males
and the pooled population were significant. Finally, females fed ACA
had less glomerulosclerosis, but not males in which glomerulosclerosis
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F IGURE 2 Changes with age in body composition due to dietary ACA. Effects of 1,000 ppm ACA diet starting at 8 months of age on
weights and body composition from 8 to 22 months of age at UT. Giving numbers of mice at 8–22 months of age: females (32–28 controls,
32–28 ACA‐treated); males (32–14 controls, 33–30 ACA‐treated). The same groups of mice were tested at 8, 12, 16, 20, and 22 months. ACA‐
treated have blue dots; controls black dots. Data are shown as mean ± SE, and weights and body fat were significantly lower, while lean mass
was significantly higher in both males and females fed the ACA diet as measured by 2‐way ANOVA using GraphPad version 7.03, which
accounted for the missing mice
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was rare even in controls (Figure 4). Lesions that were not affected
by ACA feeding, to a significant degree, included endometrial hyper-
plasia, lymphoma, pancreatic atrophy, renal mineralization, adrenal
hyperplasia, adrenal cortical degeneration, hepatic microgranuloma,
uterine cysts, uterine cystic endometrial hyperplasia, ovarian atrophy,
and ovarian pigment/lipofuscin; inferences about these negative find-
ings would require confirmation using a larger number of test cases.
2.4 | Blood glucose after refeeding
Figure 5 shows young (4 month old) males and females that were
fed either control diets (0 ppm ACA) or diets containing 400, 1,000,
or 2,500 ppm ACA for 6 weeks. Food was removed at 6 p.m., and
returned at 9 a.m. the next day. Blood glucose levels were measured
just before food was returned, and 30, 60, 180, and 360 min after it
was returned. There were no significant differences in females, but
highly significant (p < 0.002) differences in males, in which higher
levels of ACA in diets reduced blood glucose after refeeding.
2.5 | Rotarod performance with training
Rotarod testing was conducted, and average performance by sex,
group, and day is shown in Figure 6. On test day 6, after 5 days of
training, ACA females performed better than age‐matched old controls
(p = 0.0001), while male mice did not show significant benefits. Young
female controls performed better than old controls (p = 0.02), while
untreated males showed the same trend but it was not statistically sig-
nificant (p = 0.06). In a second measure of performance—mean latency
to fall averaged over the 6‐days—female mice fed ACA again per-
formed better than age‐matched controls (p = 0.02), and young female
controls performed better than old controls (p = 0.006). Again, ACA did
not lead to significant improvement in male mice, although young male
controls performed better than old (p = 0.007). In a measure of learning
rate, the rate of change across the 6‐day training period, ACA‐fed
females again performed better than age‐matched controls (p = 0.009),
and again, old female controls performed less well than young
(p = 0.01). Male learning rates did not differ among younger controls,
ACA‐treated, or old controls (all p > 0.05).
3 | DISCUSSION
3.1 | Effects of ACA on lifespan, weight, and body
composition
Key findings are that ACA improves male lifespan over a broad
range, with significant effects from diets containing 400, 1,000, or
2,500 ppm ACA. At all three doses, ACA extended lifespan much
more strongly in males than in females (Tables 1 and 2), offering an
F IGURE 3 Effects of ACA on fat depends on specific fat type. Effects of ACA on amount of fat relative to body weight in 12‐month‐old
HET3 mice at UM. Numbers of male ACA and controls are 9 each, while 8 females received ACA and 6 were controls. In subscapular fat, ACA
effects are sex‐specific: females, p = 0.71; males, p < 0.001. In mesenteric fat, ACA results in a strong reduction in both sexes: p < 0.001. In
gonadal fat, ACA effects are similar in both sexes, but weak: p = 0.074. In Inguinal fat, ACA has no effect. p values, from analysis of
covariance, reflect differences in the intercept term, which measures whether ACA alters fat pad weight after adjustment for body weight.
HET3 mice were fed diet with 1,000 ppm ACA starting at 4 months; controls were fed the base diet. Mice were fasted for 18 hr prior to
dissection. This was part of a larger study in which mice had a sham‐operation procedure at age 3 months. They were anesthetized, gonads
were exteriorized through an incision and then returned to the abdominal cavity, and the wound closed
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interesting model for sex differences. In Figure 5, ACA affects daily
postprandial increases in glucose much more in males than in
females, so males may be more amenable to metabolic benefits from
ACA. Most UM‐HET3 mice die with some form of cancer, so ACA
effects on overall lifespan probably reflect protection against neo-
plastic disease.
As in previous ITP cohorts (Harrison et al., 2009, 2014; Miller
et al., 2011, 2014; Strong et al., 2008, 2016), unknown site‐specific
differences led to male control mice living longer at UM than at UT
and TJL. Female controls in the same cohorts had very similar lifes-
pans at all three sites. This offers opportunities to explore sex‐speci-
fic aspects of aging.
If the longevity benefit of ACA were due strictly to its effects on
weight and fat, one might expect that its lifespan benefit would be
stronger in females than in males, contrary to our findings. Weights
were reduced more in females than in males (Figure 1c,d), as were
amounts of fat (Table 2, Figure 2). Thus, the lengthened survival for
ACA‐treated males vs. ACA‐treated females cannot be explained
solely by changes in body weight or fat, suggesting that the ACA
benefit on lifespan is not directly due to the effects of diet restric-
tion (DR), which increases male and female lifespans to a similar
degree in HET3 mice (Flurkey et al., 2010). Furthermore, ACA and
DR have opposite effects on blood levels of FGF21 and on voluntary
activity (Harrison et al., 2014), showing that these treatments differ.
Effects of ACA and DR may differ in HET3 mice due to carbohy-
drate vs. total diet restriction. Differences could reflect differences
in the microbiome (Smith et al., 2018) caused by the different treat-
ments, or factors still to be elucidated.
Besides ACA, significant increases in male lifespans are caused
by 17‐α‐estradiol (17aE2), aspirin, Protandim, and nordihydrogua-
iaretic acid (NDGA) (Harrison et al, 2014; Strong et al., 2008, 2016)
and by rapamycin in both male and female mice (Harrison et al.,
2014, 2009; Miller et al., 2011, 2014; Wilkinson et al., 2012). Rapa-
mycin also improves type II diabetic models (Reifsnyder et al., 2015,
2016, 2017) and brain histone modifications (Gong et al., 2015).
Effects with 17aE2 may be explained by metabolomic responses
modulated by gonadal hormones (Garratt, Tsai, Galecki, Jain, &
Miller, 2018).
3.2 | Specific physiological effects of ACA
Further key findings are from detailed studies of ACA‐treated and
control mice at each site. At UM, effects of ACA on amount of fat
relative to body weight in 12‐month‐old HET3 mice differ greatly
depending on which fat type is examined (Figure 3). In only one fat
type, subscapular, are ACA effects sex‐specific, with no effects in
F IGURE 4 Microhistopathology effects
of ACA. Lesions are compared in controls
and mice fed the 1,000 ppm ACA diet
starting at 4 months of age. Numbers of
mice: ACA old – 57 F and 54 M. The
Control group consisted of 41 male and 43
female animals, of which 11 males and 14
females were contemporaneous with the
current ACA population, and the remainder
consisted (as a preplanned strategy) of
controls from earlier cohorts also evaluated
at 22 months of age. About a third of the
mice came from each site. The values
shown are percentage of cases with the
indicated lesions, and p‐values reflect
differences between two proportions using
an asymptotically, normally distributed z
statistic, as documented in the STATA
program
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females and a highly significant reduction of fat relative to body
weight in males. Perhaps subscapular fat might be important in pre-
dicting effects of drugs on lifespan, although tests at a wider variety
of ages and with a wider variety of interventions are essential before
concluding this is the case.
Figure 4 presents pathology of mice, 22–25 months of age,
which had been fed 1,000 ppm ACA (57 F and 54 M) and three
pooled groups of age‐matched controls (43 F and 41 M). HET3 mice
show a wide range of lesions, making them a good model for normal
populations, but the sparse distribution of many specific lesions
among 22‐ to 25‐month‐old HET3 mice limits statistical power for
specific pathologies. Nevertheless, 37% of male controls had lung
tumors, and ACA reduced this by half, which might explain some of
the increase in male lifespans.
In fasting and refeeding assessed at UT (Figure 5), glucose levels
were not affected by ACA in females, but were effects in males were
highly significant, and higher amounts of ACA led to lower levels of
blood glucose. This test was done using mice at 5.5 months of age,
which had been fed ACA for only 6 weeks. While it suggests a reason
for larger effects on male lifespans, effects of ACA should be tested
over longer periods of time. Lamming et al. (2013) showed no signifi-
cant decrease of insulin sensitivity or increase in glucose with age in
either male or female HET3 mice, but these were average numbers
taken during the day when mice were not eating; it is possible that
postprandial surges in blood glucose may have effects on health and
lifespan independent of mean levels of glucose. Hormones of the
gonadal–pituitary axis may be important in sex differences. Yuan et al.
(2012) showed that female sexual maturation co‐regulated with lifes-
pan via IGF1, while Garratt, Bower, Garcia, and Miller (2017) showed
that gonadal hormones were important in differences between males
and females on several effects of ACA, including glucose homeostasis,
although endocrine effects on lifespan were not evaluated. Benefits of
ACA on rotarod performance (Jones & Roberts, 1968) are highly
significant in females but not in males (Figure 6). These data suggest
that lifespan measures do not detect the advantage given by ACA to
females in the agility tested by the rotarod.
The National Institute on Aging Interventions Testing Program
(ITP) has previously reported significant increases in lifespan caused
by aspirin, Protandim, and nordihydroguaiaretic acid (NDGA) in male
mice (Strong et al., 2008, 2016) and by rapamycin in both male and
female mice (Harrison et al., 2014, 2009; Miller et al., 2011, 2014;
Wilkinson et al., 2012). Rapamycin also improves type II diabetic
models (Reifsnyder et al., 2015, 2016, 2017) and brain histone modi-
fications (Gong et al., 2015). Acarbose and 17‐α‐estradiol (17aE2)
also extend mouse lifespans, with stronger (ACA) or exclusive
(17aE2) effects in males (Harrison et al., 2014; Strong et al., 2016).
Effects with 17aE2 may be explained by metabolomic responses
modulated by gonadal hormones (Garratt et al., 2018).
The lifespan studies of the ITP show that adhering to rigorous
standards provides strong evidence that mouse lifespan can be repro-
ducibly extended by drugs in the diet (Harrison et al., 2009, 2014;
Miller et al., 2011, 2014; Strong et al., 2008, 2016; Wilkinson et al.,
2012). The growing arsenal of drugs that extend lifespan, perhaps by
modulation of aging, cancer, or both, provides raw material for mecha-
nistic studies. It also will complement work done using mutant stocks
and dietary interventions to delineate the factors that control aging
rate in mammals and link aging to multiple forms of illness.
4 | EXPERIMENTAL PROCEDURES
4.1 | Mouse production, maintenance, and
estimation of lifespan
UM‐HET3 mice were produced at each of the three test sites as pre-
viously described (Harrison et al., 2009; Miller et al., 2011; Strong
et al., 2008), where environmental conditions are presented in detail.
F IGURE 5 ACA effects on blood glucose after refeeding. Postprandial blood glucose is reduced in males but not in females by 6 weeks on
ACA diets. Male and female UM‐HET3 mice were given one of four diets for 6 weeks starting at 4 months of age. Each point represents the
mean ± SEM of 10 mice, tested at the indicated times. Green symbols indicate diets formulated with ACA at 2,500 ppm; blue 1,000 ppm; red
400 ppm; and white 0 ppm (control). Mice were fasted from 18:00 until 9:00 the next day. Blood glucose was measured at “0” min (before
food was returned), and at 30, 60, 180, and 360 min after the food was returned to their cages. All measures were made in each sex in a
single session, but in different sessions for each sex. Data were analyzed using RM one‐way analysis of variance (ANOVA) for male and female
mice separately. In both sexes, we compared the differences between the four groups using GraphPad Prism 7.03. In females, the different
diets did not affect blood glucose levels significantly (p = 0.092). In males, the different diets had significant effects on blood glucose
(p = 0.002)
8 of 13 | HARRISON ET AL.
The dams of the test mice were CByB6F1/J, JAX stock #100009
(dams, BALB/cByJ; sires, C57BL/6J). The sires of the test mice were
C3D2F1/J, JAX stock #100004 (dams, C3H/HeJ; sires, DBA/2J). In
each site, breeding mice were fed LabDiet® 5008 mouse chow (PMI
Nutritional International, Bentwood, MO, USA). As soon as mice
were weaned, they were fed LabDiet® 5LG6 from the same source.
Males were initially housed 3 per cage, while females were housed 4
per cage; numbers declined as mice died.
Details of the methods used for health monitoring were provided
previously (Harrison et al., 2009; Miller et al., 2011; Strong et al.,
2008). In brief, each of the three colonies was evaluated four to
twelve times each year for infectious agents. All such surveillance
tests were negative for pathogens at all three sites throughout the
entire study period.
4.2 | Removal of mice from the longevity
population
Mice were removed from the study because of fighting or accidental
death (e.g., during chip implantation) or chip failure, or because they
were used for another experimental purpose. For survival analyses,
all such mice were treated as alive at the date of their removal from
the protocol and lost to follow‐up thereafter. These mice were not
included in calculations of median longevity. Overall, <3% of the
mice were removed from the longevity populations reported here,
with no significant site differences. For details, see Methods to cen-
sor mice for lifespan statistics, Supporting Information Appendix S1.
4.3 | Estimation of age at death (lifespan)
At UM and UT, mice were examined daily for signs of ill health from
the time they were set up in the experiment. At TJL, once mice were
marked as ill, they were examined daily for signs of ill health. Mice
were euthanized for humane reasons if so severely moribund that
they were considered, by an experienced technician, unlikely to sur-
vive for more than an additional 48 hr. The TJL definitive endpoint
criterion is the nonresponsiveness of a mouse to being touched, and
which is usually accompanied by one or more of the following: slow
respiration, feeling cold to the touch, a hunched‐up appearance with
matted fur, and signs of sudden weight loss, failure to eat and drink,
prominent appearing ribs and spine, and sunken hips.
The age at which a moribund mouse was euthanized was taken
as the best available estimate of its natural lifespan. Mice found
dead were also noted at each daily inspection.
4.4 | Control and experimental diets
Studies with diets done at similar times are reported here, as even
the diets with no effects act as useful controls. TestDiet®, Inc., a
division of Purina Mills (Richmond, IN, USA), prepared batches of
F IGURE 6 Effects of ACA on rotarod performance. Training on a rotarod was more effective in females fed ACA, but there was no benefit
in males. Groups of male and female UM‐HET3 mice were fed control or acarbose‐containing diets (1,000 ppm) beginning at 8 months of age
until they were 22 months of age. A group of 4‐month‐old mice fed the control diet served as the young control group. Mice were trained on
a rotarod for 5 days, with a final test done on day 6, and the latency to fall was tested. Average performance is shown by treatment, day, and
sex. Error bars represent standard errors of the means. Sample sizes for female mice were as follows: young control = 19, ACA‐fed = 27, and
old control = 27; and for male mice: young control = 19, ACA‐fed = 29, and old control = 14. Since mice with lower weights tended to have
higher rotarod times, weight was regressed onto group, and the residuals from this model used to adjust for weight in an ANCOVA comparing
averages between groups (young vs. acarbose vs. untreated)
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LabDiet® 5LG6 food containing each test substance, as well as con-
trol diets, at intervals of approximately 4 months, and shipped each
batch of food to the three test sites.
1. ACA or Acarbose was purchased from Spectrum Chemical Mfg.
Corp., Gardena, CA, product # A3965, CAS # 56180‐94‐0. It was
fed continuously at a concentration of 400, 1,000, or 2,500 mg
of ACA per kilogram of diet (ppm) to a test group of mice from
cohort 2013 starting at 8 months of age. In independent groups
of mice, it was fed at 1,000 mg/kg starting at 4 or 8 months of
age, as indicated. Probably amounts of ACA were about a third
of expected in the diet, as average concentration of acarbose in
5 batches of food pellets was 231 ± 109 (SD) ppm (intended
dose 1,000 ppm). A primary effect of acarbose is to reduce
postprandial glucose plasma levels in humans (Ruppin et al.,
1988). We observed the same result as an outcome measure in
this study (Figure 5). The combination of these results indicates
that the same pharmacokinetic and pharmacodynamic effects of
acarbose were achieved with our study design. For details, see:
Experimental diets—Acarbose, Supporting Information
Appendix S1.
2. UA or Ursolic acid was obtained from Wilshire Technologies,
Princeton NJ, CAS # 77‐52‐1. It was fed continuously at a con-
centration of 2,000 ppm to a test group of mice from cohort
2013 starting at 10 months of age.
3. HBX or 2‐(2‐hydroxyphenyl) benzothiazole was obtained from
Sigma Aldrich, Inc., St Louis, MO, USA, product # H50802, CAS
# 835‐64‐3. It was fed continuously at a concentration of 1 ppm
to a test group of mice from cohort 2012, starting at 15 months
of age. In pilot studies, diets designed to contain 1 and 10 ppm
HBX had 85% and 83% of expected amounts, respectively.
Serum of mice fed 1 ppm HBX for 8 weeks had serum levels of
89–252 ng/ml HBX, pilot mice fed 10 ppm HBX for 8 weeks had
<50 to 316 ppm, with no significant differences in serum levels
between the two groups, so 1 ppm HBX was used in the full
lifespan study.
4. I767d, INT‐767 or 6α‐ethyl‐24‐nor‐5β‐cholane‐3α,7α,23‐triol‐23
sulfate sodium salt was obtained from WIL Research, Inc., Ash-
land OH (in 2016 it was renamed Charles River Laboratories,
Ashland), and the material was a proprietary product. It was fed
continuously at a concentration of 180 ppm to a test group of
mice from cohort 2012 starting at 10 months of age. In pilot
studies, the amount of INT‐767 in the diet was 73% of the
180 ppm expected. After 8 weeks of diet containing INT‐767,
amounts in serum ranged from 254 to 869 ng/ml while control
serum contained less than 1.5 ng/ml.
4.5 | Measuring amounts of interventions
Assays for acarbose, HBX, and I767 were done at UT. The initial
drug material, food pellets, and mouse serum were sampled, pre-
pared, and assayed as detailed in the material published here on line.
Samples were quantified using HPLC with ultra violet detection. For
details, see: Measuring amounts of Interventions, Supporting Infor-
mation Appendix S1.
4.6 | Measures of body composition
At TJL, a Nuclear Magnetic Resonance (NMR) Imaging Instrument
(EchoMRI™ 3‐in‐1, EchoMRI LLC, Houston, TX, USA) was used to
measure body composition of fat, lean, free water, and total water
masses. Subjects were placed in a restrainer tube (nonanesthetized),
and three consecutive scans, 2 min in duration, were taken sequen-
tially, and data were averaged for each subject. The fat calculation is
measured as total body fat inclusive of organ and tissue fat and fatty
acids. Lean mass is muscle plus all organs. At UT, mice were placed
in a plastic cylinder (4.7 cm ID, 0.15 cm thick) in a qMRI machine
(EchoMRI, Echo Medical Systems) and scanned once for 2 min. Data
at both sites are expressed as % of body mass.
4.7 | Pathology
Using standard microhistopathological methods, J. Erby Wilkinson, a
board‐certified veterinary pathologist, examined 22‐ to 24‐month‐old
UM‐HET3 mice: 57 females and 54 males had been fed a
1,000 ppm ACA diet since they were 4 months old. There were 14
female and 11 male controls set up at the same time, plus two previ-
ous groups of age‐matched UM‐HET3 controls, for a total of 43
females and 41 males not fed ACA. Evaluation of the ACA mice and
the new set of age‐matched controls was conducted in a blinded
fashion, and the data from the old control mice combined with prior
records compiled by Dr. Wilkinson on earlier cohorts of untreated
UM‐HET3 mice for statistical purposes.
4.8 | Refeeding effects on blood glucose
Ten HET3 mice in each group were given one of four diets for
6 weeks starting at 4 months of age; the diets contained 2,500 ppm,
1,000 ppm, 400 ppm, or 0 ppm of ACA. Mice were then fasted from
18:00 to 09:00 the next morning. Tail vein blood was sampled
(around 50 microliters) at “0” minutes before returning food, and
again 30, 60, 180, and 360 min after the food was returned.
Amounts of glucose were measured in each blood sample using a
blood glucose meter One Touch Ultra Blue (Life‐Scan, Milpitas, CA,
USA).
4.9 | Rotarod
Rotarod performance was tested using the Rotamex‐5 (Columbus
Instruments, Columbus, OH, USA) for 6 consecutive days by a tech-
nician who was blinded to the treatment groups. Testing on each
day consisted of eight trials with a 10‐min rest between trials 4 and
5. Each trial began with the rotarod set at an initial rate of 4 rpm,
accelerating to a maximum 40 rpm within 300 s. The latency to fall
was recorded by the Rotamex‐5 software, and the average latency
to fall was calculated for each day.
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4.10 | Statistical methods
Significance tests about survival effects are based upon the two‐
tailed log‐rank test at p < 0.05, stratified by test site, with censored
mice included up until their date of removal from the longevity pop-
ulation. Data from male and female mice are considered separately.
In statistical tests described in the text, p values are two‐tailed and
reported without adjustment for multiple comparisons, except in Fig-
ure 6. Statistical claims related to maximum lifespan are based on
Wang et al., (2004), using the Fisher's exact test to compare the pro-
portions of surviving mice, in control and test groups, at the age cor-
responding to the 90th percentile for survival in the joint
distribution of the control and test groups. For the pooled data sets,
surviving mice were enumerated at the 90th percentile age for each
site separately, and these counts were combined for the overall Fish-
er's exact test.
4.11 | Figure 6 statistics
For statistical analysis of the rotarod performance, the average of
time‐to‐fall sessions for each animal on each day (1–6) was consid-
ered as a repeated measure in a mixed‐effect linear model with a
random intercept for males and females separately and estimated
the main effects of day, group (Old Control, Old ACA, and Young
control), and the group‐by‐day interaction. We compared the pair-
wise differences between the three groups and adjusted for multiple
testing using Tukey's Honest Significant difference method (HSD).
For details, see Statistical methods—Figure 6 statistics Supporting
Information Appendix S1.
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